AZ "COVID-19 Vaccine Shows 79% Effectiveness in US Trials... Does Not Increase Blood Clot Risk"
[Asia Economy Reporter Buaeri] Pharmaceutical company AstraZeneca (AZ) announced that its COVID-19 vaccine showed 79% efficacy in a Phase 3 clinical trial conducted in the United States.
According to major foreign media including the AP News on the 22nd, 32,449 people participated in the U.S. clinical trial, of which 20,000 were vaccinated and the rest were given a placebo for comparison.
AZ stated in a press release that its vaccine demonstrated 79% efficacy in preventing the onset of COVID-19 symptoms.
AZ also reported 100% effectiveness in preventing progression to severe cases requiring hospitalization. Among elderly people aged 65 and older, the vaccine showed 80% efficacy, higher than the overall average.
AZ explained that the vaccine was effective across all age groups, including the elderly.
AFP reported that the U.S. clinical trial did not show an increased risk of blood clot formation.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
On the same day, the University of Oxford in the UK, which co-developed the COVID-19 vaccine with AZ, announced that the Phase 3 clinical trial conducted across all age groups in the U.S., Chile, and Peru showed that AZ’s COVID-19 vaccine is safe and highly effective.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
